Insulin Glargine

In the US, Insulin Glargine (insulin glargine systemic) is a member of the drug class insulin and is used to treat Diabetes - Type 1 and Diabetes - Type 2.

US matches:

• Insulin Glargine Cartridge Systems


• Insulin Glargine Pens


• Insulin Glargine Vials


• Insulin glargine


• Insulin glargine, recombinant Subcutaneous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A10AE04

CAS registry number (Chemical Abstracts Service)

0160337-95-1

Chemical Formula

C267-H404-N72-O78-S6

Molecular Weight

6062

Therapeutic Categories

Antidiabetic agent

Insulin analogue, recombinant human

Chemical Name

21A-Glycine-30Ba-L-arginine-30Bb-L-arginineinsulin (human) (WHO)

Foreign Names

• Insulinum glarginum (Latin)
• Insulin glargin (German)
• Insuline glargine (French)
• Insulina glargina (Spanish)

Generic Names

• Insulin Glargine (OS: USAN, BAN)
• HOE 71GT (IS)
• HOE 901 (IS)

Brand Names

• Insulin Optisulin
  Aventis, Luxembourg



• Lantaus
  Sanofi-Aventis, Bangladesh



• Lantus
  Aventis, Bosnia & Herzegowina; Aventis, Bulgaria; Aventis, Czech Republic; Aventis, India; Aventis, Iceland; Aventis, Luxembourg; Aventis, Serbia; Aventis, Slovenia; Aventis, Slovakia; Sanofi Aventis, Antigua & Barbuda; Sanofi Aventis, Netherlands Antilles; Sanofi Aventis, Aruba; Sanofi Aventis, Barbados; Sanofi Aventis, Bermuda; Sanofi Aventis, Bahamas; Sanofi Aventis, Guyana; Sanofi Aventis, Haiti; Sanofi Aventis, Japan; Sanofi Aventis, Cayman Islands; Sanofi Aventis, Saint Lucia; Sanofi Aventis, Trinidad & Tobago; Sanofi Aventis, Saint Vincent & The Grenadines; Sanofi-Aventis, Austria; Sanofi-Aventis, Australia; Sanofi-Aventis, Bangladesh; Sanofi-Aventis, Bangladesh; Sanofi-Aventis, Belgium; Sanofi-Aventis, Bahrain; Sanofi-Aventis, Canada; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Chile; Sanofi-Aventis, Colombia; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Germany; Sanofi-Aventis, Denmark; Sanofi-Aventis, Ecuador; Sanofi-Aventis, Finland; Sanofi-Aventis, France; Sanofi-Aventis, United Kingdom; Sanofi-Aventis, Georgia; Sanofi-Aventis, Greece; Sanofi-Aventis, Guatemala; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Honduras; Sanofi-Aventis, Croatia (Hrvatska); Sanofi-Aventis, Hungary; Sanofi-Aventis, Indonesia; Sanofi-Aventis, Ireland; Sanofi-Aventis, Israel; Sanofi-Aventis, Italy; Sanofi-Aventis, Mexico; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Norway; Sanofi-Aventis, New Zealand; Sanofi-Aventis, Oman; Sanofi-Aventis, Panama; Sanofi-Aventis, Peru; Sanofi-Aventis, Philippines; Sanofi-Aventis, Poland; Sanofi-Aventis, Romania; Sanofi-Aventis, Russian Federation; Sanofi-Aventis, Sweden; Sanofi-Aventis, Singapore; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Thailand; Sanofi-Aventis, Tunisia; Sanofi-Aventis, Turkey; Sanofi-Aventis, Taiwan; Sanofi-Aventis, United States; Sanofi-Aventis, Venezuela; Sanofi-Aventis, Vietnam; Sanofi-Aventis, South Africa; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal; Sanofi-Aventis S.A., Spain



• Optisulin
  Sanofi-Aventis, Slovakia

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.